| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus pneumoniae | 43 | 2025 | 336 | 5.850 |
Why?
|
| Pneumococcal Infections | 28 | 2024 | 299 | 3.900 |
Why?
|
| Neisseria meningitidis | 15 | 2023 | 36 | 2.860 |
Why?
|
| Anti-Bacterial Agents | 18 | 2025 | 293 | 2.310 |
Why?
|
| Meningococcal Infections | 9 | 2021 | 24 | 2.010 |
Why?
|
| Pneumococcal Vaccines | 17 | 2025 | 278 | 1.940 |
Why?
|
| Vaccines, Conjugate | 13 | 2025 | 171 | 1.690 |
Why?
|
| Child, Preschool | 34 | 2025 | 1748 | 1.600 |
Why?
|
| Drug Resistance, Bacterial | 16 | 2025 | 135 | 1.570 |
Why?
|
| Serogroup | 20 | 2025 | 150 | 1.560 |
Why?
|
| Corynebacterium diphtheriae | 2 | 2025 | 9 | 1.540 |
Why?
|
| Meningitis, Bacterial | 5 | 2021 | 38 | 1.370 |
Why?
|
| Child | 34 | 2025 | 2242 | 1.350 |
Why?
|
| Infant | 31 | 2025 | 2244 | 1.340 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2025 | 198 | 1.340 |
Why?
|
| Haemophilus influenzae | 8 | 2023 | 42 | 1.320 |
Why?
|
| Bacterial Proteins | 12 | 2019 | 119 | 1.310 |
Why?
|
| South Africa | 56 | 2025 | 7596 | 1.250 |
Why?
|
| Humans | 76 | 2025 | 14537 | 1.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 8 | 2021 | 90 | 1.160 |
Why?
|
| Adolescent | 30 | 2025 | 2985 | 1.140 |
Why?
|
| Phylogeny | 12 | 2023 | 231 | 1.100 |
Why?
|
| Male | 37 | 2025 | 6754 | 1.080 |
Why?
|
| Multilocus Sequence Typing | 9 | 2020 | 19 | 0.970 |
Why?
|
| Respiratory Tract Infections | 8 | 2024 | 266 | 0.870 |
Why?
|
| Young Adult | 20 | 2025 | 2498 | 0.850 |
Why?
|
| Female | 34 | 2025 | 9103 | 0.850 |
Why?
|
| Penicillins | 5 | 2024 | 25 | 0.840 |
Why?
|
| Genetic Variation | 7 | 2020 | 175 | 0.840 |
Why?
|
| Sentinel Surveillance | 6 | 2024 | 115 | 0.820 |
Why?
|
| Diphtheria | 2 | 2025 | 16 | 0.810 |
Why?
|
| Infant, Newborn | 13 | 2025 | 1479 | 0.780 |
Why?
|
| Meningitis, Meningococcal | 5 | 2017 | 17 | 0.780 |
Why?
|
| Meningitis, Pneumococcal | 4 | 2025 | 20 | 0.770 |
Why?
|
| Whooping Cough | 4 | 2023 | 36 | 0.760 |
Why?
|
| Middle Aged | 22 | 2025 | 3601 | 0.750 |
Why?
|
| Aged | 17 | 2025 | 1740 | 0.750 |
Why?
|
| Influenza, Human | 6 | 2025 | 374 | 0.720 |
Why?
|
| Adult | 27 | 2025 | 5913 | 0.720 |
Why?
|
| Bacterial Capsules | 2 | 2019 | 33 | 0.710 |
Why?
|
| Neisseria meningitidis, Serogroup B | 4 | 2015 | 4 | 0.700 |
Why?
|
| Genome, Bacterial | 7 | 2024 | 32 | 0.700 |
Why?
|
| Genes, Bacterial | 5 | 2019 | 23 | 0.700 |
Why?
|
| Sequence Analysis, DNA | 13 | 2020 | 181 | 0.700 |
Why?
|
| Genotype | 16 | 2025 | 442 | 0.670 |
Why?
|
| Serotyping | 16 | 2025 | 66 | 0.660 |
Why?
|
| Hospitalization | 5 | 2024 | 418 | 0.600 |
Why?
|
| Influenza Vaccines | 3 | 2025 | 144 | 0.580 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 111 | 0.580 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 468 | 0.570 |
Why?
|
| Incidence | 12 | 2025 | 685 | 0.540 |
Why?
|
| Penicillin Resistance | 4 | 2024 | 17 | 0.520 |
Why?
|
| Meningitis | 2 | 2023 | 26 | 0.510 |
Why?
|
| DNA, Bacterial | 11 | 2021 | 53 | 0.500 |
Why?
|
| Bordetella pertussis | 4 | 2023 | 29 | 0.480 |
Why?
|
| History, 21st Century | 4 | 2025 | 42 | 0.460 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2014 | 2 | 0.450 |
Why?
|
| Acyltransferases | 1 | 2014 | 4 | 0.450 |
Why?
|
| Antigens, Bacterial | 4 | 2017 | 32 | 0.450 |
Why?
|
| Whole Genome Sequencing | 5 | 2025 | 44 | 0.440 |
Why?
|
| Genomics | 5 | 2023 | 109 | 0.420 |
Why?
|
| Bacterial Infections | 2 | 2023 | 54 | 0.390 |
Why?
|
| Molecular Epidemiology | 8 | 2025 | 47 | 0.380 |
Why?
|
| Coinfection | 3 | 2019 | 276 | 0.360 |
Why?
|
| Prospective Studies | 10 | 2025 | 1160 | 0.350 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 20 | 0.350 |
Why?
|
| Carrier Proteins | 2 | 2017 | 23 | 0.340 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2020 | 35 | 0.330 |
Why?
|
| Prevalence | 10 | 2021 | 1192 | 0.320 |
Why?
|
| Carrier State | 6 | 2021 | 92 | 0.310 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2022 | 132 | 0.300 |
Why?
|
| HIV Infections | 7 | 2022 | 5097 | 0.300 |
Why?
|
| Global Health | 4 | 2025 | 193 | 0.300 |
Why?
|
| Multiplex Polymerase Chain Reaction | 3 | 2012 | 23 | 0.290 |
Why?
|
| Streptococcus agalactiae | 3 | 2025 | 202 | 0.290 |
Why?
|
| DNA Fingerprinting | 6 | 2012 | 9 | 0.290 |
Why?
|
| Molecular Typing | 2 | 2019 | 12 | 0.280 |
Why?
|
| Cluster Analysis | 6 | 2012 | 65 | 0.260 |
Why?
|
| Virus Diseases | 2 | 2017 | 55 | 0.250 |
Why?
|
| Corynebacterium Infections | 1 | 2025 | 5 | 0.250 |
Why?
|
| Bacterial Typing Techniques | 6 | 2010 | 11 | 0.240 |
Why?
|
| Alleles | 3 | 2017 | 143 | 0.240 |
Why?
|
| Erythromycin | 1 | 2024 | 12 | 0.240 |
Why?
|
| Geographic Mapping | 1 | 2024 | 3 | 0.230 |
Why?
|
| Africa, Eastern | 2 | 2021 | 17 | 0.230 |
Why?
|
| Genetic Fitness | 1 | 2024 | 7 | 0.230 |
Why?
|
| World Health Organization | 3 | 2021 | 137 | 0.220 |
Why?
|
| Meningococcal Vaccines | 2 | 2017 | 12 | 0.220 |
Why?
|
| Amino Acid Sequence | 6 | 2017 | 139 | 0.210 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2014 | 100 | 0.210 |
Why?
|
| Streptococcal Infections | 1 | 2025 | 184 | 0.210 |
Why?
|
| Muramoylpentapeptide Carboxypeptidase | 1 | 2002 | 1 | 0.210 |
Why?
|
| Hexosyltransferases | 1 | 2002 | 1 | 0.210 |
Why?
|
| Peptidyl Transferases | 1 | 2002 | 1 | 0.210 |
Why?
|
| Aminoacyltransferases | 1 | 2002 | 3 | 0.200 |
Why?
|
| Amoxicillin | 1 | 2002 | 9 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 198 | 0.200 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 34 | 0.200 |
Why?
|
| Lactams | 1 | 2002 | 3 | 0.200 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 200 | 0.200 |
Why?
|
| Mutation, Missense | 3 | 2010 | 65 | 0.190 |
Why?
|
| Bacterial Vaccines | 1 | 2021 | 13 | 0.190 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 52 | 0.190 |
Why?
|
| Genome, Viral | 2 | 2022 | 64 | 0.190 |
Why?
|
| Africa, Southern | 1 | 2021 | 91 | 0.190 |
Why?
|
| Genetic Loci | 2 | 2019 | 11 | 0.180 |
Why?
|
| Viral Tropism | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pneumonia | 1 | 2022 | 131 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 253 | 0.180 |
Why?
|
| Vaccination | 4 | 2025 | 365 | 0.180 |
Why?
|
| Base Sequence | 3 | 2017 | 149 | 0.180 |
Why?
|
| Phenotype | 3 | 2017 | 158 | 0.180 |
Why?
|
| DNA Transposable Elements | 1 | 2020 | 4 | 0.180 |
Why?
|
| Virulence | 2 | 2017 | 25 | 0.170 |
Why?
|
| Virulence Factors | 1 | 2019 | 18 | 0.170 |
Why?
|
| Drug Resistance, Microbial | 1 | 2019 | 26 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 155 | 0.160 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 5 | 2012 | 10 | 0.160 |
Why?
|
| Rhinovirus | 1 | 2019 | 23 | 0.160 |
Why?
|
| Picornaviridae Infections | 1 | 2019 | 18 | 0.160 |
Why?
|
| Penicillin-Binding Proteins | 3 | 2010 | 7 | 0.160 |
Why?
|
| Ofloxacin | 2 | 2009 | 4 | 0.160 |
Why?
|
| Levofloxacin | 2 | 2009 | 21 | 0.150 |
Why?
|
| Dihydropteroate Synthase | 2 | 2010 | 3 | 0.150 |
Why?
|
| Fungal Proteins | 2 | 2010 | 5 | 0.150 |
Why?
|
| Pneumocystis carinii | 2 | 2010 | 9 | 0.150 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 4 | 0.150 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 4 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2010 | 16 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 176 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 6 | 0.140 |
Why?
|
| Enterovirus | 1 | 2017 | 9 | 0.140 |
Why?
|
| Empyema | 1 | 2017 | 2 | 0.140 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 4 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2017 | 11 | 0.140 |
Why?
|
| Adhesins, Bacterial | 1 | 2017 | 12 | 0.140 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antigenic Variation | 1 | 2017 | 7 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2017 | 15 | 0.140 |
Why?
|
| Bronchiectasis | 1 | 2017 | 11 | 0.140 |
Why?
|
| beta-Lactams | 2 | 2010 | 7 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 91 | 0.140 |
Why?
|
| Bacteremia | 2 | 2014 | 79 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2024 | 967 | 0.130 |
Why?
|
| Risk Factors | 5 | 2024 | 1475 | 0.130 |
Why?
|
| Smoking | 1 | 2017 | 100 | 0.130 |
Why?
|
| Neisseria meningitidis, Serogroup C | 1 | 2015 | 1 | 0.130 |
Why?
|
| Evolution, Molecular | 3 | 2020 | 60 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 146 | 0.120 |
Why?
|
| Population Surveillance | 4 | 2021 | 325 | 0.120 |
Why?
|
| Nasopharynx | 4 | 2017 | 151 | 0.120 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2024 | 42 | 0.110 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 45 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 51 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 260 | 0.110 |
Why?
|
| Tuberculosis | 2 | 2017 | 543 | 0.110 |
Why?
|
| Endemic Diseases | 2 | 2015 | 15 | 0.110 |
Why?
|
| Streptococcus | 1 | 2012 | 2 | 0.110 |
Why?
|
| Pertussis Vaccine | 2 | 2023 | 16 | 0.100 |
Why?
|
| Africa | 3 | 2019 | 376 | 0.100 |
Why?
|
| Macrolides | 2 | 2011 | 15 | 0.100 |
Why?
|
| Molecular Sequence Data | 4 | 2009 | 263 | 0.100 |
Why?
|
| DNA Gyrase | 1 | 2010 | 1 | 0.090 |
Why?
|
| DNA Topoisomerase IV | 1 | 2010 | 1 | 0.090 |
Why?
|
| Ceftriaxone | 1 | 2010 | 13 | 0.090 |
Why?
|
| Travel | 1 | 2010 | 21 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 385 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.090 |
Why?
|
| Databases, Genetic | 2 | 2020 | 22 | 0.080 |
Why?
|
| France | 2 | 2015 | 5 | 0.080 |
Why?
|
| Cephalosporins | 1 | 2008 | 4 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 106 | 0.080 |
Why?
|
| Tetracycline Resistance | 2 | 2020 | 4 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2008 | 59 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 48 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1422 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup W-135 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2008 | 6 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2022 | 171 | 0.070 |
Why?
|
| Comorbidity | 1 | 2008 | 188 | 0.070 |
Why?
|
| Asia | 2 | 2017 | 72 | 0.070 |
Why?
|
| South America | 2 | 2017 | 27 | 0.070 |
Why?
|
| Drug Resistance, Fungal | 1 | 2006 | 13 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 99 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 226 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 322 | 0.060 |
Why?
|
| Locomotion | 1 | 2024 | 3 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2024 | 179 | 0.060 |
Why?
|
| Immunization Programs | 1 | 2025 | 81 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 195 | 0.060 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.060 |
Why?
|
| Europe | 2 | 2017 | 56 | 0.060 |
Why?
|
| Liposomes | 1 | 2023 | 33 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2024 | 480 | 0.050 |
Why?
|
| Rats | 1 | 2023 | 130 | 0.050 |
Why?
|
| Transformation, Bacterial | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 26 | 0.050 |
Why?
|
| Mice | 1 | 2023 | 135 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 5 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 563 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 77 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 104 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 107 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 306 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2022 | 133 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2021 | 7 | 0.050 |
Why?
|
| Latex Fixation Tests | 1 | 2021 | 8 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 21 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 254 | 0.050 |
Why?
|
| Universities | 1 | 2021 | 34 | 0.050 |
Why?
|
| Students | 1 | 2021 | 50 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2020 | 11 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 303 | 0.040 |
Why?
|
| Poland | 1 | 2020 | 3 | 0.040 |
Why?
|
| Utah | 1 | 2020 | 3 | 0.040 |
Why?
|
| Phylogeography | 1 | 2020 | 15 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 91 | 0.040 |
Why?
|
| Animals | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Haemophilus influenzae type b | 1 | 2019 | 17 | 0.040 |
Why?
|
| Israel | 1 | 2019 | 2 | 0.040 |
Why?
|
| Hong Kong | 1 | 2019 | 2 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 20 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 15 | 0.040 |
Why?
|
| Proteins | 1 | 2019 | 20 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 24 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 30 | 0.040 |
Why?
|
| Biodiversity | 1 | 2019 | 11 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 38 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 63 | 0.040 |
Why?
|
| Genome, Human | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 95 | 0.040 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 1998 | 1 | 0.040 |
Why?
|
| Trimethoprim Resistance | 1 | 1998 | 1 | 0.040 |
Why?
|
| Population Dynamics | 1 | 2018 | 27 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 104 | 0.040 |
Why?
|
| Escherichia coli | 1 | 1998 | 30 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 81 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2018 | 52 | 0.040 |
Why?
|
| DNA, Fungal | 2 | 2010 | 3 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2017 | 8 | 0.040 |
Why?
|
| Enterovirus Infections | 1 | 2017 | 10 | 0.040 |
Why?
|
| Enterovirus D, Human | 1 | 2017 | 10 | 0.040 |
Why?
|
| Acute Disease | 1 | 2017 | 105 | 0.040 |
Why?
|
| Sputum | 2 | 2010 | 135 | 0.040 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 8 | 0.030 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 13 | 0.030 |
Why?
|
| Seasons | 1 | 2017 | 154 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 84 | 0.030 |
Why?
|
| Geography | 1 | 2017 | 60 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2016 | 31 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 102 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 370 | 0.030 |
Why?
|
| North America | 1 | 2015 | 11 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 33 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 52 | 0.030 |
Why?
|
| Viruses | 1 | 2014 | 47 | 0.030 |
Why?
|
| Lincosamides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Haemophilus Infections | 1 | 2010 | 23 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 35 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2010 | 23 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 4 | 0.020 |
Why?
|
| New Zealand | 1 | 2009 | 8 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2009 | 9 | 0.020 |
Why?
|
| United States | 1 | 2009 | 132 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 38 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2008 | 37 | 0.020 |
Why?
|
| Cross Infection | 1 | 2008 | 52 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 197 | 0.020 |
Why?
|
| Sulfanilamides | 1 | 2006 | 1 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2006 | 7 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 57 | 0.020 |
Why?
|
| Hospitals | 1 | 2006 | 103 | 0.020 |
Why?
|
| Conjugation, Genetic | 1 | 1998 | 1 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 1998 | 2 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1998 | 16 | 0.010 |
Why?
|